Fremanezumab for preventing migraine – guidance (TA764)

NICE recommend fremanezumab for preventing episodic or chronic migraine in adults, only if they have ≥4 migraine days/month & ≥3 preventive drugs have failed. It should be stopped at 12wks in episodic or chronic migraine if the frequency doesn’t reduce by 50% or 30% respectively.

SPS commentary:

Episodic migraine is classed as having ≥4, but <15 headache days per month.  Chronic migraine is classed as having at least 15 headache days per month with at least 8 of those having features of migraine.

 

This guidance updates and replaces TA631 which recommended fremanezumab for chronic migraine only.

National Institute for Health and Care Excellence